Former Puma Biotech executive gets U.S. prison term for insider trading
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology Releases Updated Corporate Presentation
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
News Release Puma Biotechnology Reports Third Quarter 2012
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology, Inc. (PBYI) Message Board | InvestorsHub
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Grants Inducement Stock Awards to New Non-Executive Employees.
Puma Biotechnology falls more than 20%
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
